about
Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heartSleep and circadian dysfunction in neurodegenerative disorders: insights from a mouse model of Huntington's diseaseShaping the role of mitochondria in the pathogenesis of Huntington's diseaseA broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice.Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington's disease.Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease.Causes of death in patients with Huntington's disease and in unaffected first degree relativesIncreased rate of suicide among patients with Huntington's disease.Neurocardiovascular deficits in the Q175 mouse model of Huntington's disease.The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model.Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.Dysfunction of the CNS-heart axis in mouse models of Huntington's disease.Suicidal behavior in prodromal Huntington diseaseBaroreceptor reflex dysfunction in the BACHD mouse model of Huntington's diseaseCardiac dysfunction in the R6/2 mouse model of Huntington's diseaseOral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis.Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease.Therapeutic perspectives for the treatment of Huntington's disease: treating the whole bodyRight ventricular dysfunction in the R6/2 transgenic mouse model of Huntington's disease is unmasked by dobutamineDrosophila as a potential model to ameliorate mutant Huntington-mediated cardiac amyloidosisMotor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) miceNeurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease.
P2860
Q27318284-CEDA628E-8F39-4C6F-A177-D4C93D1FE85DQ28383062-2B494FC7-5D6B-459A-8FDD-B1D0B9A64FADQ28384036-00176B3C-4018-4AD3-ABE1-26DC8BBB4C25Q28391627-75ADEBB9-8684-429E-AB4A-EA0EFDC9969CQ30559105-0D302E68-0C26-43EE-9AD6-99F4C07DA079Q30623834-97757AB2-2EDB-4B51-89C0-009788CE9F7AQ33594807-284AAA8C-2AF0-4FCA-98FA-1D59891770C8Q33620527-5009C58C-1AB4-421D-914C-42D6F6E0E59BQ33800209-02F6C606-D382-45FA-A292-EBA9A2703D8AQ34277801-204B4569-CFDC-4F7F-B3F5-F8C0C56FE816Q35113275-BEEB677E-9A73-455B-89F1-6C83FCD271A1Q35220835-C6A1E1E7-F5AF-43AB-8D63-CD7E7D5DA3ADQ35268087-DF16880C-E9A9-485E-8214-8CC596F92701Q35526470-6046F947-7B83-4ED7-A795-7E6180800CB2Q35745626-61A6F52B-57A7-4FEA-8477-B0838D00F747Q35892505-A1392097-96A9-4911-AAB6-D6B9FAC5AFC2Q35903061-A1F7130F-3003-4281-B579-45CF5E41AA32Q36999830-986EA814-4BB1-4BBF-A2EC-24D8CCC13571Q37702460-82CA7612-35F5-4F31-88B5-E4E12D3DD4B1Q38498245-B8CA636F-44CE-4FD4-993C-A990F9254963Q41842714-BB4AC243-9945-47AC-8AB9-5616E1F7F098Q45289568-78DE1205-2F9C-4E5D-8E9A-C7A20E185B32
P2860
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh
1982年學術文章
@zh-hant
name
Causes of death in Huntington's disease.
@en
Causes of death in Huntington's disease.
@nl
type
label
Causes of death in Huntington's disease.
@en
Causes of death in Huntington's disease.
@nl
prefLabel
Causes of death in Huntington's disease.
@en
Causes of death in Huntington's disease.
@nl
P1476
Causes of death in Huntington's disease
@en
P2093
P407
P577
1982-02-01T00:00:00Z